IBJNews

Lilly shares rise on Alzheimer's study results

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s experimental Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data by a group of academic researchers released Monday.

The magnitude of the impact fits what some physicians have said would be meaningful to patients, but Indianapolis-based Lilly still isn’t saying whether it will file for approval of the drug, called solanezumab, or instead conduct another clinical trial.

Lilly’s share price gained more than 5 percent on the news, closing Monday at $50.78.

The stock already had risen nearly 14 percent since Aug. 24, when Lilly first announced that the drug had shown some positive effects. If successful, solanezumab would be the first effective treatment for Alzheimer’s disease on the market, and could bring Lilly $5 billion to $10 billion in annual revenue.
 
“While the path forward has not been determined, we believe these data in patients with mild disease may provide a step toward a potential treatment option,” Dave Ricks, president of Lilly’s Bio-Medicines business unit, said in a prepared statement.

The drug attempts to fight Alzheimer’s disease by binding to the protein amyloid and carrying it out of patients’ brains. The build-up and clumping of excess amyloid proteins is believed to cause Alzheimer’s disease.

Lilly’s two Phase 3 clinical trials of solanezumab failed their primary goal, which was to reduce decline in the ability of both mild and moderate Alzheimer’s patient to think and do daily activities.

But in mild patients, solanezumab appeared to have some effect. In the first of the two clinical trials, solanezumab slowed cognitive decline 42 percent. But it had no effect on patients' ability to do daily activities.

In the second clinical trial, solanezumab slowed patients’ mental decline about 20 percent and their functional decline about 19 percent. However, neither result was statistically significant.

When data from both trials were pooled, the reduction in cognitive decline for mild Alzheimer’s patients was 34 percent, according to a statement released by Lilly. The improvement in daily activities was 17 percent, which was not statistically significant.

Solanezumab also showed an effect on some, but not all, so-called biomarkers, which are measurements of protein levels in patients' blood or spinal fluid. Lilly said it would present more information on the biomarker results at future medical meetings.

The data were produced by the Alzheimer's Disease Cooperative Study, a consortium of academic Alzheiemer’s researchers from around the country.

“The data results from the solanezumab Phase 3 trials were encouraging to the ADCS team,” said Dr. Rachelle Doody, a professor of neurology at the Baylor College of Medicine who presented the results Monday at a meeting of the American Neurological Association in Boston. “These results represent an important step for the medical, academic, and scientific communities in understanding brain amyloid as a target of A.D. therapies."

Dr. Martin Farlow, the associate co-director of the Indiana Alzheimer Disease Center at the Indiana University School of Medicine, said in August interview that an effective Alzheimer’s drug would need to slow patient’s decline 30 percent to 50 percent. He participated in the clinical trials of solanezumab.

“There has to be a derivable clinical benefit that’s demonstrated,” Farlow said before Lilly first released its clinical trial results for solanezumab in August. “It’s very possible that one or more of these studies may demonstrate effects that sort of point the way to the next step.”

Recent research has shown that Alzheimer’s disease begins to damage patients’ brains 10 to 20 years before they can be diagnosed with the disease. As a result, many expect Lilly will need to study solanezumab in a new clinical trial aimed at patients with pre-Alzheimer’s conditions, such as mild cognitive impairment.

Lilly officials said Monday they would continue to discuss the data from the trials of solanezumab to decide whether to file for market approval or to conduct another clinical trial.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help

ADVERTISEMENT